Renowned Physician and Key Opinion Leader to Provide Current Board with Unique and Valuable Medical and Research Perspective

BEVERLY, MA and TORONTO, Ontario – January 19, 2011 - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems for the regenerative medicine, developmental biology, stem cell research and fertility markets, today announced that David Sable, M.D., Portfolio Manager of Special Situations Life Sciences Fund, has joined Hamilton Thorne’s Board of Directors.

“Special Situations is a leader amongst U.S. life sciences funds and one of our most supportive investors. We are privileged to have Dr. Sable join our Board of Directors and provide us with his valuable insight, not only as a portfolio manager, but also as a physician and expert in cell biology,” said Meg Spencer, Chief Executive Officer of Hamilton Thorne Ltd. “Dr. Sable’s unique perspective and guidance will be especially helpful as we continue to launch groundbreaking life sciences products into new and important research markets such as cancer and developmental biology.”

In addition to his current position as Portfolio Manager at the Special Situations Life Sciences Fund, Dr. Sable was Director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey. He is board certified in both obstetrics and gynecology and reproductive endocrinology, and has held academic positions at Harvard Medical School and the Columbia University Graduate School of Arts and Sciences. Dr. Sable is a graduate of the Wharton School and the University Of Pennsylvania School Of Medicine.

“Hamilton Thorne is well positioned to become a leading life science solutions company that can help both its academic and commercial customers speed the research and discovery process for diseases such as Parkinson’s, Alzheimer’s, infertility and macular degeneration,” said Dr. David Sable, Director of Hamilton Thorne and Portfolio Manager of Special Situations Life Sciences Fund. “I look forward to joining Hamilton Thorne’s Board of Directors and being part of the Company’s continued growth and expansion, as the new products launched in late 2010, such as the Staccato™ and Stiletto™ laser systems, gain additional market adoption in 2011.”

Dr. Sable joins Hamilton Thorne’s current Board of Directors of Meg Spencer, Chairman of the Board and Chief Executive Officer of Hamilton Thorne; Diarmaid H. Douglas-Hamilton, Director, Corporate Secretary and Chief Technology Officer of Hamilton Thorne; Dean Gendron, Director, Member of Compensation Committee and Audit Committee; Bruno Maruzzo, Director and Chair of Audit Committee; Scott A Pearson, Director and Member of Audit Committee; Robert J. Potter, Director and Chair of Compensation Committee; and Daniel K. Thorne, Director and Member of Compensation Committee.

The Company also announced that it has granted Dr. Sable 150,000 stock options to purchase in pursuant of the Company’s incentive stock option plan. The options are exercisable at Cdn$0.215 per share, vest over three years, and expire ten years from the date of grant.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com) Hamilton Thorne is a leading provider of advanced laser systems for the regenerative medicine, and stem cell research markets. Hamilton Thorne's lead products, the ZILOS-tk™ and XYClone® laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, and regenerative medical research applications. The new Staccato™ and Stiletto™ laser systems are designed to broaden the Company’s markets and offer significant advantages to developmental biology, cancer research and advanced cell biology researchers.

Hamilton Thorne’s growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, McGill University, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

Return to Top

Subscribe to Our Investor Email List